Corbus Receives FDA Alignment on Cancer Drug Path

Corbus Pharmaceuticals has received alignment from the U.S. Food and Drug Administration (FDA) regarding the registration pathway for its cancer drug, CRB-701. This agreement with the FDA is a significant step forward, potentially accelerating the drug's development and path to market. The alignment provides clarity on the requirements needed for regulatory approval. This news is positive for Corbus as it advances its oncology pipeline.